

Olga Amengual

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2966357/publications.pdf>

Version: 2024-02-01

72
papers

2,229
citations

279798

23
h-index

223800

46
g-index

74
all docs

74
docs citations

74
times ranked

1850
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 1998, 79, 276-281.	3.4	256
2	Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. <i>Arthritis and Rheumatism</i> , 2012, 64, 504-512.	6.7	227
3	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	5.8	224
4	Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. <i>Arthritis and Rheumatism</i> , 1998, 41, 800-807.	6.7	124
5	The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti- β 2Glycoprotein I antibodies. <i>International Immunology</i> , 2004, 16, 1633-1641.	4.0	115
6	The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. <i>Rheumatology</i> , 2015, 54, 39-44.	1.9	104
7	Specificities, properties, and clinical significance of antiprothrombin antibodies. <i>Arthritis and Rheumatism</i> , 2003, 48, 886-895.	6.7	65
8	Nicked β 2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. <i>Blood</i> , 2004, 103, 3766-3772.	1.4	54
9	First-Line, Non-Criteria Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti- β 2-Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies Tests. <i>Arthritis Care and Research</i> , 2018, 70, 627-634.	3.4	52
10	COVID-19 pandemic in Japan. <i>Rheumatology International</i> , 2021, 41, 1-5.	3.0	51
11	Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. <i>Lupus</i> , 2015, 24, 1135-1142.	1.6	48
12	Antiphospholipid antibodies: Lessons from the bench. <i>Journal of Autoimmunity</i> , 2007, 28, 129-133.	6.5	46
13	Complement and thrombosis in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2016, 15, 1001-1004.	5.8	46
14	The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. <i>Arthritis and Rheumatism</i> , 2009, 60, 2457-2467.	6.7	41
15	The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. <i>Lupus</i> , 2015, 24, 3-9.	1.6	41
16	Antiprothrombin antibodies—are they worth assaying?. <i>Thrombosis Research</i> , 2004, 114, 533-538.	1.7	40
17	Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1126-1135.	3.4	36
18	Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 1999, 42, 2606-2611.	6.7	35

#	ARTICLE	IF	CITATIONS
19	Antiprothrombin Antibody Testing: Detection and Clinical Utility. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 335-339.	2.7	32
20	Up-Regulated Tissue Factor Expression in Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 1997, 77, 222-223.	3.4	32
21	Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2004, 23, 218-222.	2.2	30
22	Antiprothrombin antibodies and the diagnosis of antiphospholipid syndrome. <i>Clinical Immunology</i> , 2004, 112, 144-149.	3.2	27
23	Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1134-1143.	3.8	27
24	Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. <i>Autophagy</i> , 2020, 16, 946-955.	9.1	26
25	Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. <i>Rheumatology</i> , 2013, 52, 1775-1784.	1.9	25
26	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2019, 58, 969-974.	1.9	24
27	Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. <i>Thrombosis Research</i> , 2016, 146, 1-6.	1.7	23
28	Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. <i>Rheumatology</i> , 2016, 55, 1403-1411.	1.9	23
29	Research around β_2 -glycoprotein I: A major target for antiphospholipid antibodies. <i>Autoimmunity</i> , 2005, 38, 377-381.	2.6	21
30	B cells targeting therapy in the management of systemic lupus erythematosus. <i>Immunological Medicine</i> , 2020, 43, 16-35.	2.6	21
31	How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores. <i>Current Rheumatology Reports</i> , 2017, 19, 51.	4.7	20
32	Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 645-649.	1.9	19
33	Anti- β_2 glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. <i>Journal of Reproductive Immunology</i> , 2010, 84, 95-99.	1.9	17
34	Antiphospholipid syndrome, "the best prophet of the future". <i>Modern Rheumatology</i> , 2018, 28, 409-416.	1.8	17
35	Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study. <i>Rheumatology</i> , 2021, 60, 1331-1337.	1.9	17
36	IgG2 restriction of anti- β_2 -glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: Comment on the article by Sammaritano et al. <i>Arthritis and Rheumatism</i> , 1998, 41, 1513-1514.	6.7	16

#	ARTICLE	IF	CITATIONS
37	Increased Expression of Phospholipid Scramblase 1 in Monocytes from Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 1639-1645.	2.0	16
38	Ras Guanine Nucleotide- Releasing Protein 4 Is Aberrantly Expressed in the Fibroblast-like Synoviocytes of Patients With Rheumatoid Arthritis and Controls Their Proliferation. <i>Arthritis and Rheumatology</i> , 2015, 67, 396-407.	5.6	16
39	Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss. <i>Clinical Immunology</i> , 2019, 203, 37-44.	3.2	15
40	Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis. <i>Rheumatology</i> , 2020, 59, 1734-1742.	1.9	13
41	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. <i>Modern Rheumatology</i> , 2013, 23, 81-88.	1.8	12
42	Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2018, 28, 865-871.	1.8	12
43	An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 1655-1656.	6.7	11
44	Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 581-588.	2.7	11
45	Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome. <i>Current Vascular Pharmacology</i> , 2011, 9, 606-618.	1.7	9
46	Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study. <i>Rheumatology International</i> , 2022, 42, 1939-1946.	3.0	9
47	Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies. <i>Rheumatology International</i> , 2014, 34, 1225-1230.	3.0	8
48	Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study. <i>Modern Rheumatology</i> , 2017, 27, 953-960.	1.8	8
49	Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 1238-1247.	1.6	8
50	Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 164, 63-68.	1.7	7
51	Phospholipid scramblase 1 expression is enhanced in patients with antiphospholipid syndrome. <i>Modern Rheumatology</i> , 2013, 23, 81-88.	1.8	7
52	New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2021, 8, 93-99.	0.6	6
53	Current trends in medical English education and the Japan College of Rheumatology International School. <i>Modern Rheumatology</i> , 2017, 27, 1101-1105.	1.8	5
54	Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 151994.	3.4	5

#	ARTICLE	IF	CITATIONS
55	A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 2803-2805.	6.7	3
56	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2020, 30, 116-124.	1.8	3
57	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
58	Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	3
59	Pathophysiology of the antiphospholipid syndrome: roles of anticardiolipin antibodies in thrombosis and fibrinolysis. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 377-386.	0.2	2
60	Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes. <i>Rheumatology</i> , 2016, 55, 1117-1126.	1.9	2
61	Disseminated subcutaneous nodules and destructive polyarthritis. <i>BMJ: British Medical Journal</i> , 2019, 365, l1344.	2.3	2
62	Pathogenesis of Antiphospholipid Syndrome. , 2016, , 487-494.		2
63	Genetics of Antiphospholipid Syndrome. , 2006, , 521-531.		1
64	Antiphospholipid Syndrome and Atherosclerosis. , 2001, , 279-287.		1
65	Effectiveness of a Medical English Course on Communication Abilities of Graduate Medical Students. <i>Medical Science Educator</i> , 2017, 27, 209-216.	1.5	0
66	Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 47-69.	0.1	0
67	OP0213â€¦MYOFASCIA-DOMINANT: INFLAMMATION DETECTED ON WHOLE BODY MRI PREDICTS RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH DERMATOMYOSITIS. , 2019, , .		0
68	Pathogenesis of antiphospholipid syndrome. , 2021, , 555-564.		0
69	â€œEndotheliologyâ€•in Antiphospholipid Antibodies. , 2001, , 289-296.		0
70	Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. , 2017, , 189-199.		0
71	Etiopathology of the Antiphospholipid Syndrome. , 2008, , 521-535.		0
72	Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0